|
L-TGL (≤ 5.5 g/L) patients |
H-TGL (> 5.5 g/L) patients |
|
L-TGL (≤ 5.5 g/L) patients |
H-TGL (> 5.5 g/L) patients |
|
DLBCL (n =) |
12 |
84 |
NA |
10 |
22 |
|
Sex (M/F) |
7/5 |
33/51 |
0.12 |
6/4 |
11/11 |
0.71 |
Age (years) median [range] |
65 [55-80] |
70 [21-89] |
0.89 |
65 [57-80] |
72 [56-85] |
0.41 |
Lymphoma Ann-Arbor-Stage |
Lymphoma Ann-Arbor-Stage |
Lymphoma
Ann-Arbor-Stage |
Lymphoma Ann-Arbor-Stage |
|
|
|
I |
0 |
16 |
0.69 |
0 |
0 |
1 |
II |
1 |
15 |
0.69 |
1 |
2 |
1 |
III |
4 |
15 |
0.29 |
2 |
4 |
1 |
IV |
7 |
38 |
0.60 |
7 |
16 |
1 |
Central nervous system involvement (CNS) |
2 |
5 |
0.24 |
2 |
1 |
1 |
Richter syndrome (RS) |
0 |
2 |
1 |
0 |
2 |
1 |
International Prognostic Index (IPI)/Risk group (n=) |
10 (CNS excluded) |
77 (CNS and RS excluded) |
|
8 (CNS excluded) |
19 (CNS and RS
excluded) |
|
(0-1) Low |
1 |
7 |
1 |
1 |
0 |
0.31 |
(2) Low-Intermediate |
2 |
28 |
0.72 |
1 |
2 |
1 |
(3) High-Intermediate |
4 |
19 |
0.48 |
2 |
5 |
1 |
(4-5) High |
4 |
23 |
0.73 |
4 |
12 |
1 |
Total gammaglobulin level (g/L) median [range] |
4.8 [2.7-5.5] |
9.15 [5.9-19.3] |
<0.01 |
4.78 [2.7-5.5] |
9.25 [5.9-19.3] |
<0.01 |
Immunoglobulin isotype levels dosage, (n=) |
8 |
46 |
0.80 |
7 |
13 |
1 |
IgG level (g/L) median [range] |
5.4 [2.8-5.45] |
9.6
[6.4-15.7] |
<0.01 |
5.45 [2.8-5.45] |
11.4
[6.48-13.8] |
<0.01 |
IgA level (g/L) median [range] |
0.7 [0.35-5.91] |
2.3
[0.3-5.0] |
0.31 |
0.61 [0.35-5.91] |
1.49 [0.3-2.16] |
0.31 |
IgM level (g/L) median [range] |
0.4 [0.2-3.7] |
1.0
[0.2-3.3] |
0.32 |
0.46 [0.2-3.7] |
1.26 [0.25-1.35] |
0.32 |
CRP level (g/L) median [range] |
31 [3-116] |
15 [3-237] |
0.31 |
26.5 [3-116] |
37 [3-119] |
0.31 |
Ferritin level (µg/L) median [range] |
433 [73-1628] |
170
[4-3472] |
0.02 |
538.5 [73-1628] |
217.5 [93-1496] |
0.02 |
Albumin level (g/L) median [range] |
32.5 [24-40.7] |
39
[16-50] |
0.15 |
33.8 [24-40.7] |
36 [23-46] |
0.15 |
Serum Total protein level (g/L) median [range] |
58.17 [46-90] |
64.5 [46-72] |
<0.01 |
58 [46-90] |
63.5
[52-72] |
0.24 |
AG-Ratio median [range] |
6.79 [4.62-12.22] |
4.39
[1.7-7.13] |
<0.01 |
6.79 [4.62-12.22] |
4.15
[1.71-7.13] |
<0.01 |
LDH (Unit/L) median [range] |
341.5 [156-2784] |
278
[132-10091] |
0.93 |
285 [156-2784] |
366 [162-2793] |
0.77 |
Lymphocytes count (G/L) median [range] |
0.8 [0.2-2.58] |
1.26
[0.18-7.56] |
0.02 |
0.8 [0.2-2.58] |
0.92
[0.27-7.56] |
0.27 |
Follow-up (months), median [range] |
15.2 [1.23-57.77] |
55.53
[1.17-68.6] |
<0.001 |
11.7 [1.23-18.16] |
12.18 [1.17-64.23] |
0.02 |
Deaths |
10 (83.3%) |
22 (26.2%) |
0.03 |
10 (83.3%) |
22
(26.2%) |
0.03 |
Causes of deaths
Infections
DLBCL progression
Other causes
|
10 (100%)
0 (0%)
0 (0%)
|
6 (27.3%)
12 (54.5%)
4 (18%)
|
<0.001
0.35
1
|
10 (100%)
0 (0%)
0 (0%)
|
6 (27.3%)
12 (54.5%)
4 (18%)
|
<0.001
0.35
1
|